Nutra Pharma Provides Business and Compliance Updates
Nutra Pharma is providing updates regarding their business plans, accounting and compliance.
November 3, 2020 -- Plantation, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, provided updates today on their plans and progress on improving Company transparency and public company compliance.
“Because of a variety of legal issues, business issues and the fallout from the COVID-19 crisis; Nutra Pharma has been delinquent in the filing of our public company reports and financials,” commented Rik J Deitsch, Chief Executive Officer of Nutra Pharma Corporation. “We believe that information and transparency is in the best interest of the Company, our stakeholders and the investing public,” he continued. “As we work through the current issues, build sales and pursue our overall business plan; we are committed to working with our professionals to bring our company current with our reporting requirements. We have already re-engaged our outside accountants and are working with our auditors to begin catching up on all of our corporate filings. This includes quarterly reviews, annual audited financial statements and any other required filings. We believe that in order to grow as a public company we must have a renewed commitment to getting back to current status, as a fully-reporting OTC company,” he concluded.
Earlier this year, the Company announced its plans to increase brand awareness, online visibility and product messaging. This included the relaunch of their Nyloxin website last year as well as the launch of Equine Pain-Away in late 2019. They also announced the engagement of professional marketing teams that have built increased online awareness and have greatly improved product presence on their Amazon storefront.
The company now markets Nyloxin on www.Nyloxin.com as well as their Amazon marketplace at www.Amazon.com/Nyloxin. Pet Pain-Away is being marketed through www.PetPainWay.com. Equine Pain-Away has seen initial sales growth and is being marketed through www.EquinePainAway.com.
As Nutra Pharma moves forward with these projects, they will provide further updates throughout the rest of 2020.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin®, Equine Pain-Away and Pet Pain-Away. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The business update should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
# # #